PH26018A - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- PH26018A PH26018A PH38837A PH38837A PH26018A PH 26018 A PH26018 A PH 26018A PH 38837 A PH38837 A PH 38837A PH 38837 A PH38837 A PH 38837A PH 26018 A PH26018 A PH 26018A
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical composition
- ranitidine
- citrate
- unit dose
- bicarbonate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 36
- 239000000203 mixture Substances 0.000 claims description 44
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 42
- 229960000620 ranitidine Drugs 0.000 claims description 32
- 235000018342 monosodium citrate Nutrition 0.000 claims description 27
- 239000002524 monosodium citrate Substances 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 27
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical group [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 23
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims description 23
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 23
- 239000000796 flavoring agent Substances 0.000 claims description 21
- 239000012458 free base Substances 0.000 claims description 21
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 21
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 16
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 15
- 235000003599 food sweetener Nutrition 0.000 claims description 14
- 239000003765 sweetening agent Substances 0.000 claims description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 108010011485 Aspartame Proteins 0.000 claims description 7
- 239000000605 aspartame Substances 0.000 claims description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 7
- 229960003438 aspartame Drugs 0.000 claims description 7
- 235000010357 aspartame Nutrition 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- -1 alkali metal citrate Chemical class 0.000 claims description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 6
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 5
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229960001462 sodium cyclamate Drugs 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 12
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 24
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 235000019634 flavors Nutrition 0.000 description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 240000000560 Citrus x paradisi Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 235000005979 Citrus limon Nutrition 0.000 description 10
- 244000131522 Citrus pyriformis Species 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 10
- 239000004299 sodium benzoate Substances 0.000 description 10
- 235000010234 sodium benzoate Nutrition 0.000 description 10
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 229940085605 saccharin sodium Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007968 orange flavor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000015861 monopotassium citrate Nutrition 0.000 description 2
- 239000002444 monopotassium citrate Substances 0.000 description 2
- WKZJASQVARUVAW-UHFFFAOYSA-M potassium;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].OC(=O)CC(O)(C(O)=O)CC([O-])=O WKZJASQVARUVAW-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- UZLGHNUASUZUOR-UHFFFAOYSA-L dipotassium;3-carboxy-3-hydroxypentanedioate Chemical compound [K+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O UZLGHNUASUZUOR-UHFFFAOYSA-L 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8808497A FR2633181B1 (fr) | 1988-06-24 | 1988-06-24 | Composition pharmaceutique a base de ranitidine et son procede de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26018A true PH26018A (en) | 1992-01-29 |
Family
ID=9367671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38837A PH26018A (en) | 1988-06-24 | 1989-06-23 | Pharmaceutical composition |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5102665A (pt) |
| JP (1) | JPH0786086B2 (pt) |
| KR (1) | KR940002662B1 (pt) |
| AT (1) | AT396426B (pt) |
| AU (1) | AU627194B2 (pt) |
| BE (1) | BE1005691A4 (pt) |
| CA (1) | CA1329130C (pt) |
| CH (1) | CH679276A5 (pt) |
| CY (1) | CY1637A (pt) |
| CZ (1) | CZ280886B6 (pt) |
| DE (1) | DE3920626C2 (pt) |
| DK (1) | DK170223B1 (pt) |
| ES (1) | ES2015717A6 (pt) |
| FR (1) | FR2633181B1 (pt) |
| GB (1) | GB2219940B (pt) |
| HK (1) | HK33192A (pt) |
| HU (1) | HU210067A9 (pt) |
| IE (1) | IE60725B1 (pt) |
| IL (1) | IL90731A (pt) |
| IT (1) | IT1232149B (pt) |
| LU (1) | LU87541A1 (pt) |
| MY (1) | MY106412A (pt) |
| NL (1) | NL8901596A (pt) |
| NZ (1) | NZ229698A (pt) |
| PH (1) | PH26018A (pt) |
| PT (1) | PT90962B (pt) |
| SA (1) | SA90100095B1 (pt) |
| SE (1) | SE502285C2 (pt) |
| SG (1) | SG21892G (pt) |
| SK (1) | SK278823B6 (pt) |
| ZA (1) | ZA894787B (pt) |
| ZW (1) | ZW7889A1 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU627775B2 (en) * | 1988-09-20 | 1992-09-03 | Glaxo Group Limited | Pharmaceutical compositions |
| DE4027927A1 (de) * | 1990-09-04 | 1992-03-05 | Bayer Ag | Brausekomponente und verfahren zu ihrer herstellung |
| GB9019875D0 (en) * | 1990-09-11 | 1990-10-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| CA2055661A1 (en) * | 1990-12-21 | 1992-06-22 | Manley A. Paulos | Treatment of upset stomach associated with heartburn, sour stomach or acid indigestion with an effervescent h2 blocker formulation |
| US5629013A (en) * | 1991-04-04 | 1997-05-13 | The Procter & Gamble Company | Chewable calcium carbonate antacid tablet compositions |
| FR2700669B1 (fr) * | 1993-01-22 | 1995-04-14 | Tassoni Jean Pierre | Composition effervescente pour la préparation de boissons gazeuses. |
| US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
| US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
| IL112779A (en) * | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| AU712710B2 (en) * | 1996-05-17 | 1999-11-11 | Merck Sharp & Dohme Corp. | Effervescent bisphosphonate formulation |
| US5728401A (en) * | 1997-04-16 | 1998-03-17 | Ranbaxy Laboratories, Ltd. | Effervescent ranitidine formulations |
| HUP9701293A3 (en) * | 1997-07-25 | 1999-08-30 | Chinoin Gyogyszer Es Vegyeszet | New salts without unsavoury taste and pharmaceutical compositions containing them |
| US6974590B2 (en) * | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030091629A1 (en) * | 1998-03-27 | 2003-05-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6264984B1 (en) | 1999-12-06 | 2001-07-24 | Bristol-Myers Squibb Company | Effervescent histamine H2 antagonist composition |
| JP2001253826A (ja) * | 2000-03-09 | 2001-09-18 | Maruzen Pharmaceut Co Ltd | 内服用剤 |
| WO2002089823A1 (fr) * | 2001-04-27 | 2002-11-14 | Kyoto Pharmaceutical Industries, Ltd. | Methode de conservation pour un suppositoire |
| US20030104017A1 (en) * | 2001-10-26 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Epinastine formulation for oral administration |
| WO2004041244A2 (en) * | 2002-10-30 | 2004-05-21 | Pharmacia Corporation | Oral extended release tablets and methods of making and using the same |
| US20050089502A1 (en) * | 2003-08-21 | 2005-04-28 | Todd Schansberg | Effervescent delivery system |
| WO2005065319A2 (en) * | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| AU2004311879B2 (en) * | 2003-12-31 | 2010-08-05 | Cima Labs Inc. | Effervescent oral opiate dosage form |
| US7858121B2 (en) * | 2003-12-31 | 2010-12-28 | Cima Labs, Inc. | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
| JP2008500288A (ja) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20060100271A1 (en) * | 2004-11-08 | 2006-05-11 | Keith Whitehead | Stabilized aqueous ranitidine compositions |
| AU2006317530B2 (en) * | 2005-11-28 | 2011-09-01 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
| AU2007216671B2 (en) * | 2007-07-09 | 2009-07-16 | Cypress Pharmaceutical, Inc. | Pleasant-tasting ranitidine formulation |
| KR20170003414A (ko) * | 2015-06-30 | 2017-01-09 | (주)아모레퍼시픽 | 속붕해형 과립환 모발 세정용 조성물 |
| CN105997922A (zh) * | 2016-06-12 | 2016-10-12 | 佛山市腾瑞医药科技有限公司 | 一种盐酸雷尼替丁泡腾片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1962791A1 (de) * | 1969-12-15 | 1971-06-24 | Boehringer Mannheim Gmbh | Brausetabletten,Brausepulver und Verfahren zur Herstellung derselben |
| GB8313217D0 (en) * | 1983-05-13 | 1983-06-22 | Glaxo Group Ltd | Pharmaceutical compositions |
| NZ215069A (en) * | 1985-03-01 | 1988-06-30 | Reckitt & Colmann Prod Ltd | Pharmaceutical composition with histamine h 2 -receptor antagonist |
| FR2593065B1 (fr) * | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation. |
| GB8909793D0 (en) * | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
-
1988
- 1988-06-24 FR FR8808497A patent/FR2633181B1/fr not_active Expired - Lifetime
-
1989
- 1989-06-16 CH CH2263/89A patent/CH679276A5/fr not_active IP Right Cessation
- 1989-06-22 LU LU87541A patent/LU87541A1/fr unknown
- 1989-06-22 IT IT8948116A patent/IT1232149B/it active
- 1989-06-22 SE SE8902288A patent/SE502285C2/sv not_active IP Right Cessation
- 1989-06-23 GB GB8914428A patent/GB2219940B/en not_active Expired - Lifetime
- 1989-06-23 DE DE3920626A patent/DE3920626C2/de not_active Revoked
- 1989-06-23 IE IE204789A patent/IE60725B1/en not_active IP Right Cessation
- 1989-06-23 AU AU36744/89A patent/AU627194B2/en not_active Expired
- 1989-06-23 PH PH38837A patent/PH26018A/en unknown
- 1989-06-23 ES ES8902216A patent/ES2015717A6/es not_active Expired - Lifetime
- 1989-06-23 CA CA000603814A patent/CA1329130C/en not_active Expired - Lifetime
- 1989-06-23 JP JP1162481A patent/JPH0786086B2/ja not_active Expired - Lifetime
- 1989-06-23 NL NL8901596A patent/NL8901596A/nl active Search and Examination
- 1989-06-23 BE BE8900692A patent/BE1005691A4/fr not_active IP Right Cessation
- 1989-06-23 MY MYPI89000847A patent/MY106412A/en unknown
- 1989-06-23 ZW ZW78/89A patent/ZW7889A1/xx unknown
- 1989-06-23 KR KR1019890008706A patent/KR940002662B1/ko not_active IP Right Cessation
- 1989-06-23 AT AT0154489A patent/AT396426B/de not_active IP Right Cessation
- 1989-06-23 NZ NZ229698A patent/NZ229698A/en unknown
- 1989-06-23 PT PT90962A patent/PT90962B/pt not_active IP Right Cessation
- 1989-06-23 IL IL9073189A patent/IL90731A/en unknown
- 1989-06-23 DK DK314089A patent/DK170223B1/da not_active IP Right Cessation
- 1989-06-23 ZA ZA894787A patent/ZA894787B/xx unknown
-
1990
- 1990-01-29 SA SA90100095A patent/SA90100095B1/ar unknown
-
1991
- 1991-03-07 US US07/666,102 patent/US5102665A/en not_active Expired - Lifetime
- 1991-12-23 CZ CS914038A patent/CZ280886B6/cs not_active IP Right Cessation
- 1991-12-23 SK SK4038-91A patent/SK278823B6/sk unknown
-
1992
- 1992-03-04 SG SG218/92A patent/SG21892G/en unknown
- 1992-05-07 HK HK331/92A patent/HK33192A/xx not_active IP Right Cessation
- 1992-11-06 CY CY1637A patent/CY1637A/xx unknown
-
1994
- 1994-07-01 HU HU94P/P00002P patent/HU210067A9/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU627194B2 (en) | Pharmaceutical compositions | |
| US5593685A (en) | Ranitidine compositions | |
| US5225197A (en) | Pharmaceutical formulation | |
| JPH08175976A (ja) | 発泡性カップル含有のヒスタミンｈ２−拮抗剤発泡性組成物 | |
| US5468504A (en) | Effervescent pharmaceutical compositions | |
| CZ170296A3 (en) | Organoleptic acceptable pharmaceutical preparation for peroral administration | |
| EA001918B1 (ru) | Таблетка для глотания, включающая в себя парацетамол | |
| KR100238565B1 (ko) | 상부 위장관 통증을 치료하기 위한 섭취가능한 약학적 조성물 | |
| US5728401A (en) | Effervescent ranitidine formulations | |
| EP0563094B1 (en) | Pharmaceutical compositions | |
| EP0574624B1 (en) | Pharmaceutical compositions |